MOR Inhibitors
1 drugsAbout MOR
The mu-opioid receptor (MOR) is a key member of the opioid receptor family, mediating the analgesic effects of opioid drugs. It plays a central role in pain pathways, making it a significant target for pharmaceutical research and development. Activation of MOR reduces the perception of pain.
MOR is a critical protein target in pain management, but currently lacks genetic evidence directly linking its variations to specific diseases. Its established role in pain pathways underscores its importance as a drug target. Further research into MOR's function could lead to improved pain therapies.
MOR is currently targeted by one FDA-approved drug, NUCYNTA ER, a small molecule developed by COLLEGIUM PHARM INC. This drug is approved for pain indications. Further development of MOR-targeting drugs represents a key strategy in addressing pain.
Top MOR Drugs
The competitive landscape for MOR is limited, with only one company, COLLEGIUM PHARM INC, having an approved drug.
The limited competition suggests a potential opportunity for new entrants, but also indicates possible challenges in developing successful MOR-targeting drugs.
MOR Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets MOR, using small molecule modality.
Explore opportunities to develop novel MOR-targeting biologics, such as antibodies or peptides, to differentiate from existing small molecule therapies.
MOR Clinical Trials 15 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on MOR. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 6 | 5 | 1 | 0 | 83% |
| Phase 3 | 3 | 3 | 0 | 0 | 100% |
| Phase 4 | 5 | 3 | 1 | 1 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
MOR Drug Approval Timeline (2011 - 2011)
The first and only drug targeting MOR, NUCYNTA ER, was approved in 2011.
The lack of recent approvals suggests a saturated market or challenges in developing improved MOR-targeting therapies, requiring innovative approaches.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 11 (6 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on MOR. A trial counts if an approved drug acting on MOR is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.